The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders

Background: The etiology of autoimmune diseases is not fully clarified and the mechanisms underlying their initiation and progression are still obscure. It is becoming clear that in a genetic susceptible individual an environmental trigger such as infectious agent in general and viruses in particula...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2008
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23356
Acceso en línea:
https://doi.org/10.1016/j.autrev.2008.06.008
https://repository.urosario.edu.co/handle/10336/23356
Palabra clave:
Hepatitis B core antibody
Immunoglobulin G
Anamnesis
Antibody blood level
Autoimmune disease
Blood sampling
Cohort analysis
Controlled study
Hepatitis B
Hepatitis B virus
Human
Insulin dependent diabetes mellitus
Major clinical study
Multiple sclerosis
Review
Rheumatoid arthritis
Screening test
Sjoegren syndrome
Systemic lupus erythematosus
Autoimmune Diseases
Hepatitis B
Hepatitis B Antibodies
Hepatitis B virus
Humans
Autoimmunity
Hepatitis B core antibody (hbcab)
Hepatitis B virus (HBV)
Multiple sclerosis (MS)
Rheumatoid arthritis (RA)
Sjogren's syndrome (SS)
Systemic lupus erythematosus (SLE)
Type 1 diabetes (T1D)
Rights
License
Abierto (Texto Completo)
Description
Summary:Background: The etiology of autoimmune diseases is not fully clarified and the mechanisms underlying their initiation and progression are still obscure. It is becoming clear that in a genetic susceptible individual an environmental trigger such as infectious agent in general and viruses in particular could initiate the development of an autoimmune disease. Hepatitis B virus (HBV) is notorious in its association with diverse autoimmune diseases. Therefore, we aimed to determine the presence of hepatitis B core antibody (HBcAb), a seromarker for past or present infection with HBV, in a large number of sera collected from patients with different autoimmune diseases. Methods: A cohort of 675 sera samples of 5 different autoimmune diseases and healthy donors were screened for evidence of a prior infection with HBV. All samples were tested for hepatitis B core antibody (IgG) using the Monolisa anti-HBc PLUS commercial kit (Bio-Rad, Hercules, San Francisco, USA). Results: Lower percentage of HBcAb was found in sera of the autoimmune diseases when compared to normal controls. Fifteen (10.7%) from 140 normal controls were found positive for the presence of HBcAb. Two (2%) out of 98 multiple sclerosis (MS) sera were positive for the presence of HBcAb (OR: 0.17, 95%CI: 0.03-0.77, p = 0.01), 3 (2.5%) out of 117 systemic lupus erythematosus (SLE) sera (OR: 0.2, 95%CI: 0.06-0.77, p = 0.01), 4 (4.5%) out of 89 type 1 diabetes (T1D), 5 (6.1%) from 82 Sjogren's syndrome (SS) sera and 12 (8%) from 149 rheumatoid arthritis (RA) sera were positive for the presence of HBcAb. Conclusions: Our data divulge an unexpected low percentage of antibodies to HBcAg in patients with SLE, MS and T1D in comparison to healthy matched donors. This finding may raise a protective role to HBV in some autoimmune diseases i.e. hygiene theory. © 2008 Elsevier B.V. All rights reserved.